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chronic obstructive pulmonary disease (COPD, 27%), renal dysfunction (27%), 
stroke (21%), other cardiovascular disease (CVD, 78%). NNT to prevent  
one hospitalization annually (budget impact per HF patient in sample): 12 (-$89) 
ACE-inhibitor/ARB, 15 (-$60) beta-blockers, or 11 (-$123) other cardiovascular 
drugs; -27 ($92) hypertension, 11 (-$179) psychological disorder, -12 ($133) CIHD, -
12 ($118) diabetes, 13 (-$98) hyperlipidemia, -10 ($97) COPD, -8 ($116)  
renal dysfunction, -12 ($60) stroke, -8 ($322) CVD. CONCLUSIONS: Increasing 
enrollment in state Medicaid plans and other entitlement programs call for  
more deliberate, proactive and cost-effective disease and risk management  
of plan enrollees. Substantive savings to Medicaid can be achieved with  
small changes in the prevalence of common comorbid conditions or prescribing 
rates.  
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OBJECTIVES: The Affordable Care Act established the Hospital Readmission 
Reduction Program (HRRP) and the Bundled Payments for Care Initiative (BPCI), 
which may reduce Medicare payments to hospitals. We assessed these 
programs’ impact on hospital budget, focusing on the potential to reduce 
penalties via improved short-term percutaneous coronary intervention (PCI) 
outcomes. METHODS: A budget impact model was developed to quantify the 
financial penalties associated with HRRP and the difference between fee-for-
service and bundled payments under BPCI for a hospital. HRRP penalties were 
associated with excess readmissions for patients admitted with acute 
myocardial infarction (AMI), pneumonia, and heart failure. The model also 
computed payment reductions under BPCI for all PCI patients regardless of 
diagnosis. An example hospital with high volume catheterization lab (1000 
PCIs/year; 50% Medicare) and total Medicare DRG-based payments of $110 
million/year was considered. The hospital was assumed to have excess 
readmission ratios at the seventy-fifth percentile for each condition. Based on 
recent clinical trials of stent platforms, we assumed an absolute 1% reduction in 
PCI-related readmission due to AMI and revascularization over 30 days following 
PCI. RESULTS: Total HRRP penalties for the example hospital were calculated to 
be $669,025, with $199,130 additional reduction in payments under BPCI.  
Our model projected that reducing readmission post-PCIs by 1% would  
reduce excess readmission ratio for patients with AMI from 1.052 to 1.037  
and thus HRRP penalties by $80,975. Total cost of care for the 500 Medicare 
patients receiving PCI was reduced by $43,791 due to reduction of subsequent 
clinical events, a savings accrued by hospitals under BPCI, resulting in net 
hospital savings of $124,766. Achieving these savings with newer stent platforms 
would result in effective hospital savings of $156/stent. CONCLUSIONS: A 1% 
reduction in PCI-related readmissions may substantially reduce penalties  
under HRRP and BPCI. Such reductions may be achievable using new stent 
platforms.  
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OBJECTIVES: Despite national and international guideline recommendations, 
only a small proportion (estimated in 39%) of ST elevation myocardial infarctions 
(STEMI) that arrive in the 8-hour "therapeutic window" in Colombia receive 
thrombolytic treatment; our objective was to estimate the budget impact of a 
gradual implementation of this therapeutic approach. METHODS: In our excel 
based model we applied ISPOR's principles of good practice for budget impact 
analysis. The perspective was from the Colombian health system; we used a 5-
year time horizon (2012-2016). The model compared two different scenarios: 
continuing the current practice, with no increase in the proportion of 
thrombolized patients, while the other (Scenario 2) assumed a gradual increase 
(5 percentage points) of thrombolized patients, and an increase in tenecteplase 
use from (3 to 25% of all patients) along the five year period. RESULTS: Our 
estimated total cost of STEMI in Colombia for 2012, with 984 patients 
thrombolyzed nationwide, was US$728,291. With an increase in the use of 
thrombolysis (Scenario 2) the cost would increase by US$ 42,270 during the 
second year, US$87,596 during the third year, US$136,051 in the fourth year and 
US$187,716 in the fifth year (with a 15% overall increase in the number of 
thrombolyzed patients). This cost increase is due to an increase in the target 
population (estimated by official demographic projections), an increase in the 
proportion of patients with myocardial infarction receiving thrombolyisis and an 
increase in those receiving tenecteplase instead of streptokynase. 
CONCLUSIONS: Our country needs to allocate resources to prevent and treat 
cardiovascular diseases; applying current standards established in evidence-
based guidelines of myocardial infarction treatment should be an affordable 
investment.  
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OBJECTIVES: The study assessed economic burden of pharmacotherapy in 
hypertension management on the National Health insurance Scheme (NHIS) of 
Nigeria, Health Maintenance Organizations (HMOs), the individual patients, and 
the companies as well as the economies of antihypertensives selection. 
METHODS: Two hundred and fifty case notes of hypertensive patients attending 
out-patient-department of the hospital (between August 1st – November 30th, 
2011) were randomly selected. Selection criteria required that patients must  
be on at least an antihypertensive and first diagnosed after 2003. These  
were assessed for costs of pharmacotherapeutic management of hypertension  
as well as drug funding status.Requisite patients’ information extracted  
from case notes included: hospital number, age, gender, occupations, drugs, 
dosages and patients’ drug funding status. Drugs’ prices were obtained from  
the hospital billing guide. Data analysis was carried out using Microsoft  
excel and SPSS v16.0 for windows. RESULTS: Two hundred and eight of the 
selected case notes met the study criteria out of which 125 (60.1%) were males, 
while 83 (39.9%) were females. Most of the patients work for the government 98 
(47.1%). Others either work for private companies 51 (24.5%) or are self-employed 
25 (12%). Retirees constituted 11.5% of the lot while 4.8% were unemployed. 
Diuretics were the most economical at an average monthly cost per prescription 
of  858.6 ($5.51) and was closely followed by the beta-blockers at  1,101.1 ($7.07). 
The total estimated monthly cost of the antihypertensives prescribed in the 
study was  892,650 ($5730.93). HMOs having 104 (50.0%) of the cohort as enrollees 
incurred most of the cost at  446,325.0 ($2865.47). NHIS and Companies with 75 
(36.0%) and 17 (8.2%) of the enrollees respectively incurred  321,354.0 ($2,063.14) 
and  73,197.3 ($469.94). Private patients 12 (5.8%) incurred the least at  51,773.7 
($332.39). CONCLUSIONS: HMOs and NHIS incurred most of the cost of 
antihypertensives prescribed and diuretics were the most economical of all.  
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OBJECTIVES: Pharmacoeconomic analysis of two schemes antihypertensive 
therapy: diroton (lisinopril) (tab. 10 mg 128, Gedeon Richter) compared with lipryl 
(tab. 10 mg 130, BHFZ) and two regimens with fixed combinations of ACE 
(captopril) + diuretic (hypothiazide): kapozyd (tab. 50mh/25mh 130, BMS) 
compared with captopres-D (tab. 50mh/25mh 120, Darnitsa) for one year in 
Ukraine. METHODS: Cost minimization analysis, budget impact analysis and 
analysis of missed opportunities were used. RESULTS: In condition of equal 
efficacy lipryl is less expensive (costs of treatment per patient for year - 292 UAH) 
compared with diroton (costs of treatment per patient for year - 620.50 UAH). 
Indicator of missed opportunities in the transition to less expensive drug is 
1.125. According to official statistics of Ministry of Health in Ukraine there are 
12.1 millions patients with hypertension, or 32.2% of the adult population. The 
costs of lipryl treating this population are 3540 millions UAH, for diroton - 7522 
millions UAH. The transition to lipryl economy of budgetary funds will be 3982 
millions UAH. The analysis of two schemes of antihypertensive therapy with 
fixed combinations of ACE inhibitors (captopril) + diuretic (hypothiazide) shows 
that in condition of equal efficacy captopres-D is less expensive (costs of 
treatment per patient for year - 295.65 UAH) compared with kapozyd (costs of 
treatment per patient for year – 511 UAH). Indicator of missed opportunities is 
0.728. Given the number of patients with hypertension, the costs of captopres- 
D treating this population will be 3584 millions UAH, for kapozyd - 6194.6 
millions UAH. In condition of budget financing in the transition to captopres-D 
economy of budgetary funds will be 2610.6 millions UAH. CONCLUSIONS: The 
results of the analysis prove the economic feasibility of domestic 
antihypertensive drugs.  
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OBJECTIVES: The prescription of fixed-dose combinations (FDC) of 
antihypertensive drugs has increased rapidly since the relaxation of the 
prescription-term restriction. In this study, we used the opportunity of this 
policy change in Japan to examine the economic benefits of switching to FDC. 
METHODS: Claims data from 64 community pharmacies located in Tokyo were 
used to identify hypertensive patients under continuous treatment with 
angiotensin-receptor blockers (ARBs). Patients switching to FDC between 
December 2010 and April 2011 were compared to patients who did not receive 
FDC (control group). Changes in annual total and antihypertensive drug costs 
were compared for both groups, using a difference-in-differences approach to 
adjust for patient characteristics and use of concomitant medication. RESULTS: 
There were 542 patients who switched to FDC and 9664 patients in the control 
group. No significant differences were observed between the 2 groups, except for 
antihypertensive drug use patterns before the policy change. The switch to FDC 
was associated with annual savings of 6151 yen (US$87.70) in total drug costs 
and 10,420 yen (US$124.20) in antihypertensive drug costs. Approximately 20% of 
the FDC patients, however, switched from ARB alone and their treatment costs 
increased by 3795 yen (US$37.10). CONCLUSIONS: For hypertensive patients who 
required ARB-based combination therapy, switching to FDC drugs had a 
significant cost-saving effect. However, the policy change of relaxing the 
prescription-term restriction could encourage aggressive treatment, i.e., 
